Rare diseases revenue climbed 17.1% as Isturisa sales jumped 58%, while the Italian drugmaker reaffirmed its full-year 2026 targets amid a divided-board debate over a €10.7 billion takeover offer.
verifying reliability
No specialized terms available for this topic.